Ciltacabtagene autoleucel,Pomalidomide,Bortezomib,Dexamethasone,Daratumumab
Janssen
['mmsm']
#mmsm #asco23 i think overall having data on itt for car-t in myeloma is great. car-t may not be the best for aggressive disease (early deaths in first 3 months), and lack of cross over is problematic especially when we don't know subsequent therapy for at least 82 pts
Assistant professor @UAMSMyeloma. Alumni heme/onc @bcmhouston, clinical research/biostat @UMich.Focus on plasma cell disorders & health disparities